论文部分内容阅读
本文总结我院１９８６年１月～１９９３年１２月住院治疗的临床Ⅳ期舌鳞癌病例４５例，其中完成平阳霉素单药新辅助化疗组病例２０例；１７例病人未行新辅助化疗。平阳霉素总量控制在２５０～３００ｍｇ。休息３周后进行舌癌联合根治术。该方案使部分晚期病例的原发灶有所缩小，从不适合手术到可以进行手术治疗。其１、３、５年生存率分别为６０％，５０％，４０％。两组的死亡都以局部复发为主（５５％：４７．１％）。两组间的局部复发率和５年生存率差异虽无统计学意义（Ｐ＞０．０５），但从临床数字的绝对值看，新辅助化疗组结果尚不理想。这可能与病例数较少有关。同时也提示，单药诱导化疗的方案似不适用于晚期舌鳞癌的病例。我们感到，新辅助化疗的近期疗效不能预示其局部治疗中的中长期疗效，也不宜用于推测病例的生存时间。平阳霉素单药新辅助化疗在降低晚期舌癌局部复发率和提高中长期生存率方面尚无明显的进步。为此，有必要进一步改进和完善舌鳞癌的新辅助化疗方案。
This article summarizes our hospital from January 1986 to December 1993 hospitalized clinical stage Ⅳ tongue squamous cell carcinoma in 45 cases, of which complete pingyangmycin single neoadjuvant chemotherapy group of 20 patients; 17 patients without neoadjuvant chemotherapy. Pingyangmycin total control in 250 ~ 300mg. Rest for 3 weeks after tongue cancer combined radical mastectomy. The program to some of the early cases of primary lesions have been reduced, never suitable for surgery to surgery. The 1, 3, 5-year survival rates were 60%, 50%, 40%. The two groups were mainly local recurrence of death (55%: 47.1%). Although there was no significant difference between the two groups in the local recurrence rate and the 5-year survival rate (P> 0.05), the neoadjuvant chemotherapy group's results were not satisfactory from the absolute clinical value. This may be related to the small number of cases. At the same time also suggests that the single-drug induction chemotherapy does not seem to be suitable for advanced cases of tongue squamous cell carcinoma. We feel that the recent efficacy of neoadjuvant chemotherapy can not predict the long-term efficacy of its local treatment, and should not be used to predict the survival of patients. Pingyangmycin monotherapy neoadjuvant chemotherapy in the reduction of local tongue cancer recurrence rate and improve long-term survival rate no significant improvement. Therefore, it is necessary to further improve and perfect the neoadjuvant chemotherapy regimen of tongue squamous cell carcinoma.